How cagrilintide (an amylin analogue) compares to and stacks with semaglutide (a GLP-1 agonist), with a look at the CagriSema trial readouts and what they…
How cagrilintide (an amylin analogue) compares to and stacks with semaglutide (a GLP-1 agonist), with a look at the CagriSema trial readouts and what they mean for the next generation of weight-management peptides.
Cagrilintide is a long-acting amylin analogue under investigation for chronic weight management. Semaglutide is a GLP-1 receptor agonist already widely studied in the same space. They act on different gut-brain pathways, and the most interesting clinical data so far comes from combining them — the CagriSema program. This overview covers how each molecule works, where they differ, and what the published trial readouts have actually shown.
Amylin is a pancreatic hormone co-secreted with insulin. It slows gastric emptying, suppresses post-meal glucagon, and signals satiety in the hindbrain. Cagrilintide is engineered for once-weekly dosing and binds both amylin and calcitonin receptors.
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted from the gut in response to food. GLP-1 agonists like semaglutide enhance glucose-dependent insulin secretion, slow gastric emptying, and act on hypothalamic appetite circuits. The two pathways are complementary rather than redundant — which is the entire rationale for combining them.
CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. Phase 2 data published in The Lancet (2021) reported markedly greater weight loss with the combination than with either component alone in adults with type 2 diabetes.
Phase 3 readouts from the REDEFINE program (2024–2025) in adults with obesity reported mean weight loss in the ~20–23% range at 68 weeks for the combination — competitive with the highest-performing GLP-1/GIP agents in head-to-head context, though absolute numbers vary by trial population.
The 2025–2026 weight-management pipeline is increasingly multi-pathway: GLP-1 monotherapy (semaglutide), GLP-1/GIP dual agonists (tirzepatide), GLP-1/GIP/glucagon triple agonists (retatrutide), and GLP-1 + amylin combinations (CagriSema). Each combination targets a slightly different physiology, and head-to-head data is still being generated.
Cagrilintide is not FDA-approved as a finished drug product as of this writing. In the U.S. research-peptide market it is supplied for research, investigational, or licensed professional use only — never for personal consumption from a retailer. Reputable suppliers ship every batch with a third-party Certificate of Analysis and clear labeling.
If you are evaluating cagrilintide for a research protocol, treat lab transparency, U.S. compounding partner, and written purchase agreements as table stakes — the same diligence that applies to any peptide in this category.
Editorial overview only. All peptide products referenced are intended solely for research, investigational, or licensed professional use. Conduct your own research and consult a trusted, licensed medical practitioner before any personal or clinical use.
| Peptide | Category | Summary |
|---|---|---|
| Semaglutide | Metabolic & Weight | Semaglutide is a long-acting GLP-1 receptor agonist with one of the deepest clinical-trial datasets in metabolic medicine. It supports glucose-dependent insulin secretion, slows gastric emptying, and acts on central appetite pathways. |
| Tirzepatide | Metabolic & Weight | Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. By engaging two incretin pathways at once, head-to-head trials suggest larger average effects on weight and HbA1c than single-pathway GLP-1 agonists. |
| Retatrutide | Metabolic & Weight | Retatrutide is an investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data published in NEJM showed the largest average weight reductions reported for any incretin-class molecule to date. |
Published 2026-06-27 by the Clarity Wellness editorial team. Approximate reading time: 8 minutes. Our sourcing and review policy is published at /editorial-standards.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.